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Key Points
Question
What are the treatment effects of a 3-dimensional stent retriever in conjunction with local aspiration-based
mechanical thrombectomy vs aspiration-based thrombectomy alone as a primary modality for
endovascular stroke intervention?
Findings
In this randomized clinical trial of 198 patients, aspiration-assisted stent retrieval was demonstrated to be
noninferior in safety and effectiveness compared with direct aspiration for stroke intervention.
Meaning
Aspiration is a reasonable frontline therapy choice in stroke thrombectomy, in addition to stent retrieval.
Abstract
Importance
The treatment effects of individual mechanical thrombectomy devices in large-vessel acute ischemic stroke
(AIS) remain unclear.
Objective
To determine whether the novel 3-dimensional (3-D) stent retriever used in conjunction with an aspiration-
based mechanical thrombectomy device (Penumbra System; Penumbra) is noninferior to aspiration-based
thrombectomy alone in AIS.
Design, Setting, and Participants
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This randomized, noninferiority clinical trial enrolled patients at 25 North American centers from May 19,
2012, through November 19, 2015, with follow-up for 90 days. Adjudicators of the primary end points
were masked to treatment allocation. Patients with large-vessel intracranial occlusion AIS presenting with
a National Institutes of Health Stroke Scale (NIHSS) score of at least 8 within 8 hours of onset underwent
1:1 randomization to 3-D stent retriever with aspiration or aspiration alone. The primary analyses were
conducted in the intention-to-treat population.
Interventions
Mechanical thrombectomy using intracranial aspiration with or without the 3-D stent retriever.
Main Outcomes and Measures
The primary effectiveness end point was the rate of a modified Thrombolysis in Cerebral Infarction
(mTICI) grade of 2 to 3 with a 15% noninferiority margin. Device- and procedure-related serious adverse
events at 24 hours were the primary safety end points.
Results
Of 8082 patients screened, 198 patients were enrolled (111 women [56.1%] and 87 men [43.9%]; mean
[SD] age, 66.9 [13.0] years) and randomized, including 98 in the 3-D stent retriever with aspiration group 
and 100 in the aspiration alone group; an additional 238 patients were eligible but not enrolled. The
median baseline NIHSS score was 18.0 (interquartile range, 14.0-23.0). Eighty-two of 94 patients in the 3-
D stent retriever and aspiration group (87.2%) had an mTICI grade of 2 to 3 compared with 79 of 96 in the
aspiration alone group (82.3%; difference, 4.9%; 90% CI, −3.6% to 13.5%). None of the other measures
were significantly different between the 2 groups. Device-related serious adverse events were reported by
4 of 98 patients in the 3-D stent retriever with aspiration group (4.1%) vs 5 of 100 patients in the aspiration
only group (5.0%); procedure-related serious adverse events, 10 of 98 (10.2%) vs 14 of 100 (14.0%). A
90-day modified Rankin Scale score of 0 to 2 was reported by 39 of 86 patients in the 3-D stent retriever
with aspiration group (45.3%) vs 44 of 96 patients in the aspiration only group (45.8%).
Conclusions and Relevance
The present study provides class 1 evidence for the noninferiority of the 3-D stent retriever with aspiration
vs aspiration alone in AIS. Future trials should evaluate whether these results can be generalized to other
stent retrievers.
Trial Registration
clinicaltrials.gov Identifier: NCT01584609
Introduction
Current US Food and Drug Administration (FDA)–cleared reperfusion therapies for acute ischemic stroke
(AIS) are limited to the intravenous administration of alteplase, which is a human tissue plasminogen
activator, within 3 hours from symptom onset and the use of endovascular mechanical thrombectomy
devices within 8 hours from ictus, including stent retrievers and an aspiration-based mechanical
thrombectomy device (Penumbra System; Penumbra). Until recently, only intravenous alteplase was
supported by class 1A evidence as a treatment for AIS, whereas the utility of mechanical thrombectomy
devices was not widely accepted. Subsequently, 6 randomized clinical trials (RCTs), including Multicenter
Randomized Clinical Trial of Endovascular Treatment for Acute Ischemic Stroke in the Netherlands (MR
CLEAN), Endovascular Treatment for Small Core and Proximal Occlusion Ischemic Stroke (ESCAPE),
Extending the Time for Thrombolysis in Emergency Neurological Deficits—Intra-Arterial (EXTEND-IA),
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Solitaire With the Intention for Thrombectomy as Primary Endovascular Treatment (SWIFT PRIME),
Endovascular Revascularization With Solitaire Device Versus Best Medical Therapy in Anterior
Circulation Stroke Within 8 Hours (REVASCAT), and Trial and Cost Effectiveness Evaluation of Intra-
arterial Thrombectomy in Acute Ischemic Stroke (THRACE), confirmed the superiority of mechanical
thrombectomy over best medical therapy alone in improving clinical outcomes after large-vessel occlusion
(LVO) strokes. In recognition, the American Heart Association updated its guidelines and recommended
that for patients with anterior circulation stroke due to confirmed LVO affecting the internal carotid artery
or middle cerebral artery M1 segment, mechanical thrombectomy should be undertaken as soon as possible
for maximal benefit within 6 hours from symptom onset.
Most of the interventions in these trials used stent retrievers, with primary aspiration being used in only a
few patients. However, current common practice combines stent retrievers and local aspiration or starts
with direct aspiration alone. To date, data from RCTs are lacking a comparison of the safety and
effectiveness of these 2 principal modalities in acute stroke intervention. The aim of this RCT was to
determine whether the safety and efficacy of the novel Penumbra 3-dimensional (3-D) stent retriever
(Penumbra, Inc) when used in conjunction with an aspiration-based mechanical thrombectomy device, was
noninferior to the aspiration-base mechanical thrombectomy device alone in acute stroke intervention.
Methods
Study Design
The Penumbra Separator 3D trial was a prospective, randomized, single-blinded, active controlled,
noninferiority design, multicenter study at 25 centers in the United States. The full study protocol is
available in Supplement 1. Patients presenting with symptoms of AIS who had evidence of an LVO (≥2.5
mm in diameter) in the cerebral circulation underwent 1:1 randomization to the 3-D stent retriever with
aspiration arm or the aspiration only arm, with the latter serving as the active control group. At the time of
the trial design, no reference standards existed against which a novel stent retriever should be tested
because the current state of knowledge about the superiority of the Solitaire and Trevo stent retrievers over
medical treatment alone was only subsequently established. As such, the Penumbra aspiration system
alone was an acceptable choice for an active control. Each treated patient was followed up for 90 days
after randomization. The US FDA approved the trial protocol, and each participating center obtained local
institutional review board approval. Procedures followed were in accordance with institutional guidelines.
The participants or their legal representatives provided signed written informed consent.
The purpose of this study was to assess the safety and effectiveness of the 3-D stent retriever as a
component of the Penumbra System in the revascularization of LVO in AIS. The goal was to demonstrate
the noninferiority of the 3-D stent retriever with aspiration to aspiration alone in effecting reperfusion in
ischemic stroke as defined by a posttreatment modified Thrombolysis in Cerebral Infarction (mTICI) grade
of 2 to 3 (range, 0-3, with higher scores indicating a greater degree of revascularization). The margin of
inferiority was set at 15%.
A data safety monitoring board (DSMB) and clinical events committee reviewed the incoming safety data
on an ongoing basis, and if the DSMB thought that the risks of the intervention outweighed the benefits,
the DSMB had the authority to request examination of efficacy results to assess the risk of the technology
and recommend a modification to the device, a revision of the protocol, or termination of the study at its
discretion. On June 23, 2016, the DSMB voted unanimously to halt further enrollment in the 3-D trial after
concluding that based on the available adjudicated data for 86% of the target enrollment, the prespecified
primary end points had been met and recruiting additional participants would not change the outcome of
the trial.
Participants
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To be included, patients had to be 18 to 85 years of age; demonstrate symptoms consistent with an AIS
with a National Institutes of Health Stroke Scale (NIHSS) score of at least 8.0 (range, 0-42, with higher
scores indicating greater stroke severity), be refractory to or not eligible for intravenous alteplase therapy,
be expected to undergo arterial puncture within 8 hours from symptom onset, and demonstrate
radiographically an LVO (≥2.5 mm in diameter) in the intracranial circulation. Exclusion criteria are
described in the eMethods in Supplement 2.
Each center was required to complete 2 initial cases with the 3-D stent retriever with aspiration that were
not included in trial analytics. Before enrollment, angiographic confirmation of LVO was required.
Randomization and Masking
Participants were randomly assigned using an online access tool in a 1:1 ratio to 3-D stent retriever with
aspiration or aspiration alone using randomly ordered blocks of sizes 2 and 4. The schedule was stratified
by center. A patient was considered to be enrolled after a treatment arm was assigned from the
randomization system. Owing to the nature of the procedure, involved investigators were not masked to
the treatment arm. Imaging review was performed while masked to all clinical information except stroke
side.
Procedures
For patients assigned to the 3-D stent retriever with aspiration arm, the thrombectomy procedure has been
previously described in detail. Similarly to other stent retrievers, the 3-D stent retriever is a laser-cut
nitinol device attached to a wire pusher, but it possesses significantly less metal on its circumference and
has 4 intraluminal, 3-D chambers designed to maximize clot engagement and extraction into the
reperfusion catheter while minimizing contact with vessel intima. In contrast, the other stent retrievers on
the market rely on their radial expansion to push the clot against the vessel wall and into the stent struts.
For patients assigned to the aspiration only arm, the thrombectomy procedure by aspiration has also been
described in detail elsewhere. The trial aspiration system included the second-generation 4MAX, 5MAX,
and 5MAX ACE reperfusion catheters (Penumbra, Inc). In summary, an appropriately sized reperfusion
catheter, with or without a separator, was used to remove the clot via pump aspiration; many cases did not
involve a separator because the direct aspiration as a first pass technique (ADAPT) principle was used.
The reperfusion catheter was designed to capture and evacuate the clot using aspiration, whereas the
separator was designed to prevent the reperfusion catheter from clogging for automated, continuous
aspiration. When used, the separator was passed back and forth at the tip of the reperfusion catheter at the
proximal margin of the occlusion under aspiration. If the 3-D stent retriever with aspiration or aspiration
alone was unable to revascularize the target vessel, the use of other rescue therapies was considered to be a
protocol deviation. Moreover, any use of intra-arterial tissue plasminogen activator or non–FDA-approved
treatments was considered to be a treatment failure.
The mTICI grades were assessed before mechanical thrombectomy and at completion of the
revascularization. All patients were followed up for 90 days from the time of randomization. Patients
underwent evaluation for neurologic and/or functional status immediately before randomization, at 24
hours and at 7 days (or day of discharge from the hospital, whichever was earlier) after randomization, and
at 30 days (±10 days) and 90 days (±10 days) after randomization.
Outcomes
The primary study end points were angiographic revascularization of the occluded target vessel
immediately after the procedure as defined by an mTICI grade of 2 or 3 and incidence of device- and
procedure-related serious adverse events within 24 hours after the procedure. Angiograms were sent to an
independent core laboratory masked to treatment allocation for adjudication of mTICI flow. The secondary
study end points were the proportion of patients with functional independence as defined by a modified
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Rankin Scale (mRS) score of no greater than 2 at 90 days after the procedure (range, 0-6, with higher
scores indicating greater functional disability), all-cause mortality, and the incidence of symptomatic
intracranial hemorrhage (ICH). Other secondary measures included good clinical outcome at 30 days after
the procedure as defined by an improvement in the NIHSS score of 10.0 points or more at discharge, an
NIHSS score of 0 to 1.0 at discharge, or a 30-day mRS score of 0 to 2 and good neurologic outcome at 90
days after the procedure as defined by an mRS score of no greater than 2 or an improvement on the NIHSS
score of 10.0 or more points. Follow-up non–contrast-enhanced computed tomography was performed a
mean (SD) of 24 (12) hours after randomization, and scans were reviewed by the core laboratory to assess
ICH based on European Cooperative Acute Stroke Study definitions. A symptomatic ICH was defined as
24-hour evidence on computed tomography of any ICH that was associated with a worsening of 4.0 points
or more in the NIHSS score. In the event of death (n = 5) or unavailable NIHSS score (n = 2) at the 24-hour
follow-up, the clinical events committee adjudicated the ICH.
Statistical Analysis
The sample size calculations assumed that 80% of the patients in the 3-D stent retriever with aspiration and
aspiration only groups would experience success (mTICI grade, 2-3). Based on a binomial noninferiority
analysis with a margin of 15%, a study of 103 patients per group would have 85% power with a 1-sided α
of .05. The sample size was adjusted to 230 patients to account for attrition.
The objective of the statistical analysis was to assess whether the effectiveness of 3-D stent retriever with
aspiration was noninferior to aspiration alone as defined by an mTICI grade of 2 to 3. The primary
effectiveness analysis was the difference between the 3-D stent retriever with aspiration and the aspiration
alone (control) groups. A binomial comparison was used to test the null hypothesis that the difference in
the proportions of the groups (3-D stent retriever with aspiration minus aspiration alone) was no greater
than −0.15 (ie, revascularization in the 3-D stent retriever with aspiration group is worse than in the
aspiration alone group) vs the 1-sided alternative that differences in the proportions of the groups were at
least −0.15. This comparison was equivalent to evaluating that the lower bound of the 90% CI for the
difference was greater than −15%.
Baseline characteristics were summarized by treatment group and for the total population. Comparisons
among treatment groups were performed using the Fisher exact test for categorical data and Wilcoxon rank
sum test for continuous data. Exact binomial 95% CIs and comparisons are 2-sided. The level of
significance was set at P < .05. Patients with intra-arterial thrombolytic use or with vessel access failure
underwent analysis as treatment failures for the primary end point (mTICI grades). Most patients had the
primary end point, but more patients in the 3-D stent retriever with aspiration than aspiration alone arms
were missing 90-day mRS scores. Sensitivity analyses were performed, imputing participants as treatment
failures. Additional details of the statistical analysis, including the statistical analysis plan, are found in
eMethods in Supplement 2. Analyses were conducted using SAS software (version 9.2; SAS Institute).
Results
A total of 8082 patients underwent screening, of whom 198 were enrolled at 25 centers in the United
States from May 19, 2012, to November 19, 2015 (87 men [43.9%] and 111 women [56.1%]; mean [SD]
age, 66.9 [13.0] years). Among the enrolled patients, 98 (49.5%) were randomized to the 3-D stent
retriever with aspiration arm and 100 (50.5%) to the aspiration alone arm. The CONSORT flowchart (
Figure 1) summarizes patient enrollment and follow-up in the trial.
Baseline characteristics for the primary analysis are shown in Table 1. The intention-to-treat population
included all 198 patients. The median baseline NIHSS score was 18.0 (interquartile range [IQR], 14.0-
23.0), with 76 patients (38.4%) having a score of 20.0 or greater. Overall, 133 patients (67.2%) received
intravenous alteplase. The median baseline non–contrast-enhanced computed tomographic Alberta Stroke
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Program Early CT Score was 8 (IQR, 7-9; possible range, 0-10, with higher scores indicating lack of
completed infarct). Of the target vessels, 153 (77.3%) were the middle cerebral artery and 39 (19.7%) were
the internal carotid artery (Table 1). Before onset of treatment, 185 of 197 patients (93.9%) had
angiographic core laboratory–assessed flow mTICI grade of 0 or 1 at the site of the target occlusion.
Patients presented to the participating hospital 0 to 459 minutes after symptom onset, with a median time
of 111 minutes (IQR, 45-226 minutes).
In general, the baseline characteristics were similar in both treatment groups. No significant between-
group differences were noted except the affected hemisphere; 39 patients in the 3-D stent retriever with
aspiration group (39.8%) had a left hemisphere occlusion vs 59 in the of the aspiration only group (59.0%;
P = .01). Age, baseline NIHSS and Alberta Stroke Program Early CT scores, site of arterial occlusion, and
glucose levels were comparable across both treatment groups. The median time from symptom onset to
reperfusion mTICI grades of 2 to 3 for all patients was 305 minutes (IQR, 221-400 minutes) (314 minutes
[IQR, 221-398 minutes] for 3-D stent retriever with aspiration vs 290 minutes [IQR, 230-400 minutes] for
aspiration alone). Table 1 shows additional procedural times. Stenosis was observed proximal to the
primary occlusion in 20 of 197 patients (10.2%); of these 20 patients, interventions to address the stenosis
were performed in 6.
After treatment with the assigned device, the primary effectiveness outcome (flow mTICI grade, 2-3) was
achieved in 161 of 190 patients (84.7%) (3-D stent retriever with aspiration: 82 of 94 [87.2%]; aspiration
only: 79 of 96 [82.3%]; difference, 4.9% [90% CI, −3.6% to 13.5%]). Substantial reperfusion (mTICI
grade, 2b-3) was achieved in 144 of 190 patients (75.8%) (3-D stent retriever with aspiration: 77 of 94
[81.9%]; aspiration alone: 67 of 96 [69.8%]; difference, 12.1% [90% CI, 2.0%-22.2%]) (Figure 2). End-of-
procedure revascularization to an mTICI grade of 2 to 3 was achieved in 175 of 192 patients (91.1%) (3-D
stent retriever with aspiration: 87 of 95 [91.6%]; aspiration alone: 88 of 97 [90.7%]; difference, −1.1%
[90% CI, −11.3% to 12.6%]), with substantial improvement (mTICI grade, 2b-3) in 158 of 192 patients
(82.3%) (3-D stent retriever with aspiration: 83 of 95 [87.4%]; aspiration alone: 75 of 97 [77.3%];
difference, 10.1% [90% CI, −2.0% to 21.6%]). Table 2 summarizes the immediate postprocedure results in
both treatment groups.
The primary safety end point was the incidence of device- and procedure-related serious adverse events
within 24 hours of the procedure. As shown in Table 3, no significant difference occurred between
treatment groups in the 24-hour device-related serious adverse event rates, including 4 of 98 patients
(4.1%) in the 3-D stent retriever with aspiration group vs 5 of 100 (5.0%) in the aspiration only group.
eTable 1 in Supplement 2 shows the types of device-related adverse events. The between-group differences
were unremarkable. The overall rate of functional independence (mRS score, 0-2) at 90 days was 83 of
182 (45.6%), with no significant differences between the 3-D stent retriever with aspiration and aspiration
alone groups (39 of 86 [45.3%] vs 44 of 96 [45.8%]; P > .99). Similarly, no significant differences in 90-
day mortality occurred (3-D stent retriever with aspiration: 19 of 98 [19.4%]; aspiration alone: 26 of 100
[26.0%]; P = .31) or in the rates of symptomatic ICH (3-D stent retriever with aspiration: 3 of 98 [3.1%];
aspiration alone: 5 of 100 [5.0%]; P = .72). Good clinical outcomes at 30 days after the procedure were
achieved in 113 of 197 patients (57.4%); good neurologic outcome at 90 days, in 111 of 182 patients
(61.0%) (Table 3); with no difference between treatment groups.
To evaluate the effect of baseline conditions on treatment effect and functional outcome, subgroup
analyses were performed for the primary variable, mTICI grades of 2 to 3. The subgroups used for these
analyses were age (<65 or ≥65 years), baseline NIHSS score (<20.0 or ≥20.0), and site of occlusion. We
found no evidence of any significant heterogeneity of treatment effect in any of the prespecified subgroups
(eFigure 1 in Supplement 2). Kaplan-Meier estimates of the probability of death among patients (per
protocol) are shown in eFigure 2 in Supplement 2. There was no significant difference in mRS score
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distributions (eFigure 3 in Supplement 2) or baseline characteristics and process times (eTable 2 in
Supplement 2). Per-protocol analyses of primary and secondary outcomes are detailed in Supplement 2
(eTables 3 and 4). Additional study details are provided in eTables 5 to 10 in Supplement 2.
Discussion
Despite the evidence supporting endovascular treatment in AIS, the comparative safety and effectiveness
of the individual FDA-approved mechanical thrombectomy devices remain unclear. Furthermore, growing
evidence suggests that aspiration might be an equally safe and effective initial strategy during mechanical
thrombectomy.
Our study demonstrates that aspiration-assisted stent retrieval using the 3-D stent retriever is not inferior to
direct aspiration alone for revascularization of LVO strokes. Our results indicate that the difference in
achieving mTICI grades of 2 to 3 between intervention arms was small at 4.9%, with a lower bound of the
90% CI of −3.6%, well within the prespecified margin for noninferiority of −15% (Table 2 and Figure 1).
Similarly, the rates of device-related serious adverse events were almost identical, and other safety
measures were comparable (Table 3). Based on these data, we conclude that the 3-D stent retriever used in
conjunction with aspiration is noninferior to the aspiration system alone.
In the control arms of 5 recently published RCTs, functional independence rates were found to range from
26% to 32%. In the meta-analysis of MR CLEAN, ESCAPE, EXTEND-IA, SWIFT PRIME, and
REVASCAT from the Highly Effective Reperfusion evaluated in Multiple Endovascular Stroke Trials
(HERMES) collaboration, in the control group (n = 653), 26.5% achieved functional independence,
whereas in the endovascular thrombectomy group (n = 634), which primarily used currently available stent
retrievers, 46% achieved functional independence and 71% achieved reperfusion to mTICI grades of 2b or
3. The HERMES authors highlighted that “stent-retrievers were the main device used across all 5 trials
thus stent-retrievers constitute the benchmark against which future thrombectomy approaches should be
measured.”  A single RCT that focused on thromboaspiration as the primary endovascular treatment
modality vs best medical therapy (The Randomized, Concurrent Controlled Trial to Assess the Penumbra
System’s Safety and Effectiveness in the Treatment of Acute Stroke [THERAPY]) was halted early after
loss of equipoise. Although failing to reach significance for aspiration, the directions of effect for all
prespecified outcomes were suggestive of a potential benefit.
Our study compares well with the HERMES analyses of efficacy. Functional independence as measured
using an mRS score of no greater than 2 occurred in 45.6%, with no significant differences between the 3-
D stent retriever with aspiration and aspiration alone groups (45.3% vs 45.8%; P > .99). Similarly, we
achieved reperfusion using the benchmark of mTICI grades of 2b to 3 in 75.8% (3-D stent retriever with
aspiration: 81.9%; aspiration alone: 69.8%; P = .06). These findings suggest that primary stent retrieval
with aspiration and primary aspiration alone may be reasonable initial strategies for revascularization
during mechanical thrombectomy for LVO causing AIS. Aspiration as a primary treatment modality may
acquire greater significance if the initial studies suggesting that aspiration alone may be a more cost-
effective choice as frontline therapy are confirmed. Larger studies are therefore needed to further explore
the clinical efficacy and cost-effectiveness of the different mechanical strategies.
Limitations
Similar to recent randomized endovascular stroke trials, a major limitation of this study is that the
participating investigators were not masked to the treatment arm. Use of masked core laboratory staff for
the primary trial end points and a clinical events committee minimizes any potential bias inherent in an
open label trial. In addition, although at the time of the planning of our trial an mTICI reperfusion grade of
2 to 3 was an acceptable primary end point, the current standards are higher and include mTICI grades 2b
and 3 only. As such, we performed a post hoc analysis for the mTICI grade 2b to 3 end point, which
(p1729)
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suggested that we would have similarly met the stipulated noninferiority requirements. Of importance,
although this trial provides the first direct comparison of a stent retriever vs aspiration system, these results
are specific to the 3-D stent retriever and should not be extrapolated to other stent retriever devices. This
issue has been addressed by another confirmatory trial. Finally, our noninferiority margin of 15% may
have been too wide, because such a difference in reperfusion rates could lead to significant differences in
clinical outcomes.
Conclusions
The Penumbra Separator 3D RCT provides the first class 1 evidence, to our knowledge, comparing the
treatment effects of a 3-D stent retriever when used with aspiration vs aspiration alone. The results of both
arms appear comparable and seem to be within a similar range of outcomes from the treatment arms of the
recent positive endovascular RCTs.
Notes
Supplement 1.
Trial Protocol
Supplement 2.
eMethods. Exclusion Criteria, Device Use, and Statistical Analysis
eTable 1. Device-Related Adverse Events (Intention to Treat)
eTable 2. Baseline Patient Characteristics and Process Times (Per Protocol)
eTable 3. Primary Outcomes (Per Protocol)
eTable 4. Safety and Secondary Outcomes (Per Protocol)
eTable 5. Definition and Distribution of mTICI Scores (Intention to Treat)
eTable 6. Number of Patients Randomized by Center
eTable 7. Comparison of Baseline Characteristics of Analyzed and Missing Data (Intention to
Treat)
eTable 8. mRS Sensitivity Analyses (Intention to Treat)
eTable 9. Screening Results
eTable 10. Classification of Intracebral Hemorrhages
eFigure 1. Distribution of Primary End Point (mTICI 2-3) Treatment Effect Across the Prespecified
Subgroups (Intention to Treat)
eFigure 2. Kaplan-Meier Estimates of the Probability of Death in Patients (Intention to Treat)
eFigure 3. Functional outcomes at 90 days, According to Modified Rankin Scale Score (Intention
to Treat)
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Figure 1.
Open in a separate window
CONSORT Flow Diagram
mRS indicates modified Rankin Scale; 3-D, 3-dimensional.
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Table 1.
Baseline Patient Characteristics
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Abbreviations: ASPECTS, Alberta Stroke Program Early CT (computed tomography) Score; ED, emergency
department; ICA, internal carotid artery; IQR, interquartile range; MCA, middle cerebral artery; M1, main MCA
stem; M2, second-order MCA branch; mRS, modified Rankin Scale; mTICI, modified Thrombolysis in Cerebral
Infarction; NIHSS, National Institutes of Health Stroke Scale; PCA, posterior cerebral artery; 3-D, 3-dimensional.
SI conversion factor: To convert glucose to millimoles per liter, multiply by 0.0555.
Scores range from 0 to 42, with higher scores indicating greater stroke severity.
Scores range from 0-10, with higher scores indicating lack of completed infarct.
Scores range from 0 to 6, with higher scores indicating greater functional disability.
Scores range from 0 to 3, with higher scores indicating a greater degree of revascularization.
Characteristic Patient Group
All
 
(N = 198)
3-D Stent Retriever With
Aspiration
 
(n = 98)
Aspiration
Alone
 
(n = 100)
Age, mean (SD), y 66.9 (13.0) 67.3 (13.6) 66.5 (12.5)
Female, No./total No. (%) 111/198
(56.1)
57/98 (58.2) 54/100 (54.0)
Baseline NIHSS score
Median (IQR) 18.0 (14.0-
23.0)
18.0 (14.0-21.0) 18.0 (14.5-
23.5)
≥20.0, No./total No. (%) 76/198 (38.4) 35/98 (35.7) 41/100 (41.0)
Baseline ASPECTS, median (IQR) 8 (7-9) 8 (7-9) 8 (7-9)
Admission systolic blood pressure, mean (SD), mm
Hg
142.5 (20.4) 143.1 (20.8) 141.8 (20.1)
Prestroke mRS score, No. (%)
0 192/197
(97.5)
95/97 (97.9) 97/100 (97.0)
1 4/197 (2.0) 2/97 (2.1) 2/100 (2.0)
Hypertension, No./total No. (%) 155/198
(78.3)
74/98 (75.5) 81/100 (81.0)
Admission glucose level, median (IQR), mg/dL 120 (104-
146)
122 (104-145) 119 (104-
147)
Diabetes, No./total No. (%) 53/198 (26.8) 24/98 (24.5) 29/100 (29.0)
Atrial fibrillation, No./total No. (%) 96/198 (48.5) 52/98 (53.1) 44/100 (44.0)
Site of primary occlusion determined by core
laboratory, No./total No. (%)
ICA 39/198 (19.7) 15/98 (15.3) 24/100 (24.0)
MCA M1 126/198
(63.6)
65/98 (66.3) 61/100 (61.0)
MCA M2 27/198 (13.6) 15/98 (15.3) 12/100 (12.0)
PCA 2/198 (1.0) 1/98 (1.0) 1/100 (1.0)
Basilar 2/198 (1.0) 1/98 (1.0) 1/100 (1.0)
a
b
c
a
b
c
d
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Figure 2.
Primary and Key Secondary End Point Differences Between Treatment Groups
ICH indicates intracranial hemorrhage; mRS, modified Rankin Scale; mTICI, modified Thrombolysis in Cerebral
Infarction; and 3-D, 3-dimensional.
Indicates primary end point (with 90% CI).
Indicates post hoc end point (with 90% CI).
Indicates secondary end point (with 95% CI).
a
b
c
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Table 2.
Primary and Post Hoc Efficacy Outcomes
mTICI Grade
(Analysis)
No (%) of Patients Difference, % (90%
CI)All 
 
(n = 198)
3-D Stent Retriever With
Aspiration
 
(n = 98)
Aspiration
Alone
 
(n = 100)
2-3 (ITT) 161/190
(84.7)
82/94 (87.2) 79/96 (82.3) 4.9 (−3.6 to 13.5)
2b-3 (ITT) 144/190
(75.8)
77/94 (81.9) 67/96 (69.8) 12.1 (2.0 to 22.2)
2-3 (PP) 151/173
(87.3)
77/87 (88.5) 74/86 (86.0) 2.5 (−5.9 to 10.8)
2b-3 (PP) 137/173
(79.2)
73/87 (83.9) 64/86 (74.4) 9.5 (−0.6 to 19.6)
Abbreviations: ITT, intention to treat; mTICI, modified Thrombolysis in Cerebral Infarction; PP, per protocol; 3-D, 3-
dimensional.
Scores range from 0 to 3, with higher scores indicating a greater degree of revascularization.
Indicates post hoc end points.
a
b
b
a
b
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Table 3.
Safety and Secondary Outcomes
Outcome No. (%) of Patients Difference, % (95%
CI)All
 
(n = 198)
3-D Stent Retriever With
Aspiration
 
(n = 98)
Aspiration
Alone
 
(n = 100)
Device-related SAE at 24
h
9/198 (4.5) 4/98 (4.1) 5/100 (5.0) −0.92 (−6.71 to 4.88)
Procedure-related SAE at
24 h
24/198
(12.1)
10/98 (10.2) 14/100 (14.0) −3.80 (−12.86 to
5.27)
All-cause mortality at 90 d 45/198
(22.7)
19/98 (19.4) 26/100 (26.0) −6.61 (−18.24 to
5.01)
Symptomatic ICH within
24 h
8/198 (4.0) 3/98 (3.1) 5/100 (5.0) −1.94 (−7.40 to 3.53)
30-d Good clinical
outcome
113/197
(57.4)
58/97 (59.8) 55/100 (55.0) 4.79 (−9.00 to 18.59)
90-d mRS score 0-2 83/182
(45.6)
39/86 (45.3) 44/96 (45.8) −0.48 (−14.98 to
14.01)
90-d Good neurologic
outcome
111/182
(61.0)
56/86 (65.1) 55/96 (57.3) 7.82 (−6.30 to 21.94)
Abbreviations: ICH, intracranial hemorrhage; mRS, modified Rankin Scale; SAE, serious adverse event; 3-D, 3-
dimensional.
Indicates a National Institutes of Health Stroke Scale (NIHSS) score of no more than 1 or at least a 10.0-point
improvement at discharge (range, −28 to 27, with positive values indicating less impairment at discharge), or a 30-d
mRS score of no more than 2 (range, 0 to 6, with higher scores indicating greater functional disability).
Indicates an mRS score of no more than 2 or at least a 10.0-point improvement on the NIHSS score.
a
b
a
b
